Humana Q4 adjusted EPS and revenue beat analyst expectations

Overview

• Health insurer's Q4 adjusted revenue beat analyst expectations

• Adjusted EPS for Q4 beat analyst expectations

• Company anticipates FY 2026 Medicare Advantage membership growth of 25%

Outlook

• Humana projects FY 2026 GAAP EPS of at least $8.89; 'at least $9.00' on an Adjusted basis

• Company expects FY 2026 individual Medicare Advantage membership growth of 25%

• Humana anticipates continued growth in CenterWell and Medicaid platforms

Result Drivers

• CENTERWELL EXPANSION - Growth of over 25% in CenterWell Senior Primary Care patients, including acquisition impact

• MEDICAID FOOTPRINT - Expanded Medicaid footprint now spans 13 states, including future launches in Georgia and Texas

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 19 "hold" and 2 "sell" or "strong sell"

• The average consensus recommendation for the managed healthcare peer group is "buy."

• Wall Street's median 12-month price target for Humana Inc is $288.00, about 58.9% above its February 10 closing price of $181.30

• The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release: ID:nBw3Rl2Fya

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.